PAG
FBRX icon

Private Advisor Group’s Forte Biosciences FBRX Stock Holding History

Private Advisor Group’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-748
Closed -$24K – 1988
2022
Q2 		$24K Buy
+748
New +$23.8K ﹤0.01% 2067
2020
Q3 		– Sell
-1
Closed – – 2185
2020
Q2 		$0 Sell
1
-27
-96% -$12.1K ﹤0.01% 3863
2020
Q1 		$13K Hold
28
– – ﹤0.01% 1398
2019
Q4 		$6K Buy
+28
New +$6.34K ﹤0.01% 1619

Other funds holding FBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
OWP
Old Well Partners Charlotte, North Carolina $4.55M AUM 27.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Private Advisor Group's FBRX Position: Q3 2022 in Review

Private Advisor Group sold out of Forte Biosciences (FBRX) in Q3 2022, closing a stake of 748 shares — an estimated $24K sold.

Private Advisor Group first reported a position in FBRX in Q4 2019 and held it in 4 quarters. The position peaked at $24K in Q2 2022. 33 funds tracked by Wall St. Rank hold FBRX as of Q3 2022.

  • Private Advisor Group reported no remaining Forte Biosciences position as of Q3 2022 after selling out during the quarter.
  • Private Advisor Group sold 748 Forte Biosciences shares in Q3 2022, an estimated $24K.
  • Private Advisor Group first reported a position in Forte Biosciences in Q4 2019 and held it in 4 quarters.
  • Private Advisor Group's Forte Biosciences position peaked at $24K in Q2 2022.
  • 33 funds tracked by Wall St. Rank held Forte Biosciences as of Q3 2022.

Based on Private Advisor Group's 13F filing for Q3 2022, filed 14 Oct 2022.